Biovica International AB (BIOVIC-B) Fair Value & Analysis
Healthcare · SE · Market cap 117M SEK
Fair value as of: Jul 9, 2026
From 1 valuation models · updated 12 days ago
Share price +6.9% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.2750 – kr 0.7200 · fair‑value band kr 0.1190 – kr 0.2295 · the kr 0.4480 price screens above the kr 0.1785 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Biovica International AB (BIOVIC-B) currently trades at kr 0.4480, while our model-based Fair Value estimate is kr 0.1785, implying the stock looks roughly 60.2% overvalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 10.9M SEK. Revenue grew 45.7% year over year. It earns a return on equity of -83.9%. The balance sheet holds a net cash position of 66.1M SEK. Fundamentals as of Jul 9, 2026
Our scenario range runs from kr 0.1190 (bear case) to kr 0.2295 (bull case); at kr 0.4480, the current price sits above that range. The share trades about 50% below its 52-week high and 66% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at -60%, BIOVIC-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Biovica International AB reported revenue of kr 13.4M in FY2026 versus kr 2.0M in FY2022, a compound +59.9%/yr. Reported net income was −kr 69.9M in FY2026.
Is BIOVIC-B fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$37.56 | HK$26.11 | -30% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biovica International AB (BIOVIC-B) undervalued?
What is the fair value of BIOVIC-B?
What is the quality score of BIOVIC-B?
What is the revenue of Biovica International AB (BIOVIC-B)?
What is the net profit margin of BIOVIC-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Biovica International AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.